
Binger Straße 173
D-55216 Ingelheim
Germany
boehringer-ingelheim.de
Project leader
 |
|
Dr. Ralf Heilker |
Lead Identification |
Phone |
+49 7351 54 5590 |
Fax |
+49 7351 83 5590 |
E-Mail |
|
|
|
Co-Project leader
 |
|
Dr. Mario Beilmann |
Nonclinical Drug Safety 88397 Biberach an der Riss |
Phone |
+49 7351 547726 |
Fax |
+49 7351 54 98686 |
E-Mail |
|
|
|
Project staff
 |
|
Prof. Bastian Hengerer |
CNS Diseases Research |
Phone |
+49 7351 54 4742 |
Fax |
+49 7351 83 4742 |
E-Mail |
|
|
|
 |
|
Prof. Frank Gillardon |
CNS Diseases Research |
Phone |
+49 7351 54 8460 |
Fax |
+49 7351 83 8460 |
E-Mail |
|
|
|
 |
|
Dr. Tobias Hildebrandt |
Target Discovery Research |
Phone |
+49 7351 54 547819 |
Fax |
+49 7351 54 547819 |
E-Mail |
|
|
|
 |
|
Dr. Florian Meier
|
Toxicology & Assay development |
Phone |
+49 7351 54 143219 |
|
|
E-Mail |
|
|
|
 |
|
Dr. Rolf Göggel |
Research Networking 88397 Biberach an der Riss
Germany
|
Phone |
+49 7351 54 96889 |
Fax |
+49 7351 54 5997 |
E-Mail |
|
|
|
Institute presentation
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with high unmet medical need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
Boehringer Ingelheim's successes in research & development continuously strengthen our portfolio of medications and offer patients true therapeutic benefit. The company focuses on six major research areas: CardioMetabolic diseases, Central nervous system diseases, Immunology and Inflammation, Infectious diseases, Oncology and Respiratory diseases.
boehringer-ingelheim.com